Pharma R&D Annual Review


The 34th Annual Review is here!

This year’s report analyses a pipeline in transition — down overall, stronger in late stages, and reshaped by company and regional shifts.

Understand what changed and what it means for your 2026 strategy.

Download the report today →

''
Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
Inside the 2026 Annual Review:
  • The first pipeline decline in decades
  • Strong growth across Phase II and III
  • China’s continued rise in new drug leadership
  • Movement across the top 10 pharma pipelines
  • Therapeutic areas gaining ground — and those retreating 
Darkened Qualified calendar. Please allow all cookies to use functionality.

To enable the booking feature, please enable all cookies in your browser.